The Journal of Experimental Medicine
for flow cytometry > invitrogen
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online
doi:10.1084/jem.20072681
The Journal of Experimental Medicine, Vol. 205, No. 1, 7-12
The Rockefeller University Press, 0022-1007 $30.00
© Sekaly
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 497K)
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sekaly, R.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sekaly, R.-P.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

COMMENTARY

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

Rafick-Pierre Sekaly

R.-P. Sekaly is at Université de Montréal, CR-CHUM, Institut National de la Santé et de la Recherche Médicale U743, Montréal, Québec H2X1P1, Canada

CORRESPONDENCE R.P.S.: rafick-pierre.sekaly{at}umontreal.ca


ABSTRACT
The world of human immunodeficiency virus (HIV) vaccines has suffered a baffling setback. The first trial of a vaccine designed to elicit strong cellular immunity has shown no protection against infection. More alarmingly, the vaccine appeared to increase the rate of HIV infection in individuals with prior immunity against the adenovirus vector used in the vaccine. A new study in this issue suggests that a different vaccine approach—using a DNA prime/poxvirus boost strategy—induces polyfunctional immune responses to an HIV immunogen. The disappointing results of the recent vaccine trial suggest that a more thorough assessment of vaccine-induced immune responses is urgently needed, and that more emphasis should be placed on primate models before efficacy trials are undertaken.



Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Article

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
Alexandre Harari, Pierre-Alexandre Bart, Wolfgang Stöhr, Gonzalo Tapia, Miguel Garcia, Emmanuelle Medjitna-Rais, Séverine Burnet, Cristina Cellerai, Otto Erlwein, Tristan Barber, Christiane Moog, Peter Liljestrom, Ralf Wagner, Hans Wolf, Jean-Pierre Kraehenbuhl, Mariano Esteban, Jonathan Heeney, Marie-Joelle Frachette, James Tartaglia, Sheena McCormack, Abdel Babiker, Jonathan Weber, and Giuseppe Pantaleo
J. Exp. Med. 2008 205: 63-77. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS